Ocular immunology and inflammation · 2025
Treatment of Non-Infectious Uveitis Macular Edema Using Two Doses of Triamcinolone Acetonide: Comparative Study.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eduardo de Souza Carlos, Zanetti Patricio de Macedo Barbara, Viana de Sousa Monique, Naomi Morimoto Lisangela, Lima Luiz H, Muccioli Cristina
Аннотация
PURPOSE: To compare the efficacy and safety of two doses of intravitreal triamcinolone acetonide (2 mg and 4 mg) in treating non-infectious uveitic macular edema.
METHODS: This prospective, randomized study assigned patients to Group A (4 mg; 0.1 mL) or B (2 mg; 0.05 mL) of intravitreal triamcinolone acetonide. Participants were assessed at 7, 30, 60, and 90 days post-procedure. Central retinal thickness (CRT), best-corrected visual acuity (BCVA), recurrence rate, adverse events (intraocular pressure [IOP] and cataract), and quality-of-life assessment (VFQ-NEI) were analyzed.
RESULTS: Thirty-two eyes (16 per group) completed the 3-month follow-up. Group A demonstrated a significantly greater reduction in CRT at the end of follow-up (p = 0.026). Group B had higher recurrence rates (Group A: Four [25%] eyes vs. Group B: eight [50%] eyes; [p = 0.137]). Although both groups showed transient IOP spike at 7 days post-procedure, no cases of intraocular hypertension were noticed at the end of the study. BCVA outcomes were comparable between groups (p = 0.192). The quality-of-life assessment questionnaire revealed significant improvement in near vision (p = 0.031) and mental health (p = 0.021) subscales in Group A.
CONCLUSION: Group A (4 mg) showed better clinical results in terms of anatomic outcomes, recurrence rates, and quality of life measures compared to Group B (2 mg). Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up.
METHODS: This prospective, randomized study assigned patients to Group A (4 mg; 0.1 mL) or B (2 mg; 0.05 mL) of intravitreal triamcinolone acetonide. Participants were assessed at 7, 30, 60, and 90 days post-procedure. Central retinal thickness (CRT), best-corrected visual acuity (BCVA), recurrence rate, adverse events (intraocular pressure [IOP] and cataract), and quality-of-life assessment (VFQ-NEI) were analyzed.
RESULTS: Thirty-two eyes (16 per group) completed the 3-month follow-up. Group A demonstrated a significantly greater reduction in CRT at the end of follow-up (p = 0.026). Group B had higher recurrence rates (Group A: Four [25%] eyes vs. Group B: eight [50%] eyes; [p = 0.137]). Although both groups showed transient IOP spike at 7 days post-procedure, no cases of intraocular hypertension were noticed at the end of the study. BCVA outcomes were comparable between groups (p = 0.192). The quality-of-life assessment questionnaire revealed significant improvement in near vision (p = 0.031) and mental health (p = 0.021) subscales in Group A.
CONCLUSION: Group A (4 mg) showed better clinical results in terms of anatomic outcomes, recurrence rates, and quality of life measures compared to Group B (2 mg). Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up.